礼来口服GLP-1药物Orforglipron在三大关键2型糖尿病试验中展现出卓越的血糖控制与减重效果

美股速递
Jun 09

在针对2型糖尿病的三项关键性临床试验中,礼来公司的口服GLP-1受体激动剂Orforglipron(研发代号LY3502970)表现卓越,其降低糖化血红蛋白(a1c)与控制体重的效果均显著优于对照组。

该药物为每日一次的口服制剂,其便利性有望为患者提供注射剂GLP-1药物之外的重要新选择。试验数据显示,接受Orforglipron治疗的患者在预设的疗效观察期内,其血糖水平得到有效改善,同时体重也实现了具有临床意义的下降。

这一积极结果进一步巩固了礼来在糖尿病与肥胖症治疗领域的领先地位,并为Orforglipron后续向监管机构提交上市申请奠定了坚实的数据基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10